Donna Wolk leads a research program focused on improving infectious disease diagnostics and preventing infections before they occur. Her team is internationally recognized for advancing clinical laboratory innovations and diagnostic algorithms and has led or contributed to clinical trials resulting in FDA approval of more than 35 in‑vitro diagnostic devices. The program also supports translational research through a sample biorepository and the LOGIC analytic datasets, which integrate clinical, operational, financial, and social data to address critical medical and quality questions. A distinguished microbiologist and national leader in laboratory medicine and healthcare strategy, Wolk plays key clinical and research roles within Geisinger’s integrated healthcare system, advancing population health and value-based care while serving as a trusted public voice on emerging diagnostic technologies and the diagnosis of life‑threatening infections.